New trial data suggests Thalomid and IMIDs affect myeloma at every stage of the disease.

Discusses results of clinical trials showing that Thalomid and other immunomodulatory drugs demonstrated potential as a treatment targeting the myeloma cell-host interaction and bone marrow microenvironment, according to a study presented by Celgene scientists at the 9th International Myeloma meeting in Spain. Study suggestion that a reduction of the monoclonal protein concentration of at least 50 percent occurred in a third of patients with refractory multiple myeloma after Thalomid monotherapy.